Skip to content
Radio Logo

The Dime

Bryan Fields
Latest episode

309 episodes

  • The Dime

    Throughput Is Not Profit, Ingredient-Based Manufacturing, and Fixing the Leak ft. Matt Erickson

    11/17/2026 | 47 mins.
    Throughput is the easiest extraction metric to celebrate and one of the easiest ways to hide a losing system.
    An operator can move more biomass while sacrificing recovery, product quality, margin, and the ability to respond when demand shifts. Matt Erickson argues that extraction should be designed around the business outcome, then separated into repeatable ingredient and formulation workflows that make costs, handoffs, and constraints visible.
    This week we sit down with Matt Erickson
    Profit before raw speed
    THCA and HTE workflows
    Proving equipment claims
    Alternate opening hook: A faster extraction line can make the scoreboard look better while the business gets worse.
    Chapters
    00:00 Throughput vs Performance
    02:49 Profitability as the North Star
    07:39 Standardizing Across MSOs
    08:20 Customize Equipment Standardize Process
    12:25 Tribal Knowledge and Scalability
    18:04 The Leaky Bucket
    19:07 Dirty Data Inside the Lab
    21:13 The Cost of Chasing Efficiency
    22:40 Ingredient Based Manufacturing
    24:17 THCA and HTE
    28:51 Separating Extraction From Formulation
    30:03 Formulating With Demand
    32:52 Assembly Line Specialization
    34:44 Verification and Pharmaceutical Logic
    36:09 Shortening the Feedback Loop
    37:02 Why Generic SOPs Fail
    38:15 Upgrade or Rebuild
    40:59 The Cookie Cutter Equipment Problem
    42:16 Sunk Costs and Phased Upgrades
    44:34 Proving the ROI
    47:42 The Root Cause Before the Quote
    Guest Links
    Evolved Extraction website
    Matthew Erickson on LinkedIn
    Matthew Erickson on Instagram
    Our Links
    The Dime Podcast — website
    Bryan Fields on X
    The Dime on X
    The Dime on YouTube
    The Dime on Instagram
    Newton Insights — insights for extraction teams

    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
  • The Dime

    Europe's 51st State, EU GMP, and Building Before the Market Arrives ft. Michael Sassano

    11/06/2026 | 56 mins.
    The expensive decision rarely looks intelligent before the market needs it.
    Operators can build for the regulations in front of them, or for the direction regulators are already moving. Across global medical cannabis markets, internal labs, stability programs, EU GMP manufacturing, and control of distribution are beginning to separate companies that can scale profitably from those that can only trade product.
    This week we sit down with Michael Sassano
    Europe's 51st state
    Pharmaceutical discipline
    EBITDA before volume
    Chapters
    00:00 Schedule III and Europe
    02:15 Europe as the 51st state
    07:44 Building for pharmaceutical lead times
    11:44 What EU GMP changes
    16:14 Creativity inside the rulebook
    19:40 Why pharma owns the lab
    22:50 The economics of internal validation
    26:34 Could the United States adopt this model
    28:34 The EU GMP supply shortage
    32:32 Regulators close the conversion loophole
    35:23 Distribution consolidation begins
    39:46 The missing vertical
    43:25 A country by country strategy
    46:37 What SOMAI will not do
    49:42 Why extracts start with full bud
    51:38 The rules become the moat
    53:15 Europe as a totality of growth
    55:21 Where to find Michael
    Guest Links
    SOMAÍ Pharmaceuticals website
    Michael Sassano / SOMAÍ on X
    SOMAÍ on Instagram
    SOMAÍ on LinkedIn
    SOMAÍ on Facebook
    Our Links
    The Dime Podcast — website
    Bryan Fields on X
    The Dime on X
    The Dime on YouTube
    The Dime on Instagram
    Newton Insights — insights for extraction teams

    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
  • The Dime

    How AYRLOOM Built Its Advantage in New York Cannabis ft. Eddie Brennan

    10/26/2026 | 44 mins.
    A 115-year farm discovered that preserving the legacy meant letting a new crop compete with it.
    Ayrloom reached Beak & Skiff's revenue scale in three years, then forced the family to reallocate capital, people, land, and drying space while cannabis regulation kept the businesses legally separate.
    The advantage was not cannabis expertise. It was years of beverage manufacturing scars, retail-grade quality systems, and relationships strong enough to survive a crowded New York shelf.
    This week we sit down with Eddie Brennan
    Capital behind rapid growth
    Quality before repeat purchase
    Defending premium through compression
    Chapters
    00:00 Sharing one farm across two companies
    02:18 Cannabis versus apples for space
    04:24 Three-year growth catches a 115-year business
    07:33 Growth, cash, and what breaks
    09:52 Why cannabis expertise is overrated
    12:09 Beverage scars become an operating advantage
    15:17 Grocery-grade quality control
    19:10 Consistency wins repeat purchase
    21:04 Making cannabis approachable
    23:43 The reverse gateway claim
    25:29 Where cannabis beverages belong
    27:22 Regulation and high-dose drinks
    30:14 Why Ayrloom stays narrow and deep
    34:22 Price compression and retail health
    37:05 When an in-house brand outruns co-manufacturing
    39:39 What changes in a new market
    42:10 The pressure of a fifth-generation legacy
    44:35 Where to find Ayrloom
    Guest Links
    Eddie Brennan - ayrloom
    Our Links
    The Dime Podcast — website
    Bryan Fields on X
    The Dime on X
    The Dime on YouTube
    The Dime on Instagram
    Newton Insights — insights for extraction teams
    Follow The Dime for more conversations on cannabis business, operations, and international markets.
    Share this episode with an operator rethinking their edibles.

    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
  • The Dime

    Who Benefits From Federal Cannabis Limbo? ft. Jay Rosenthal

    10/14/2026 | 53 mins.
    Federal cannabis reform is supposed to open the same door for everyone. The current market says otherwise.
    The largest operators do not share one political agenda, and some of the barriers they complain about are also widening their moats. As capital markets, international medical standards, and state regulation collide, the operators built for uncertainty may be the ones hardest to dislodge.
    This week we sit down with Jay Rosenthal
    Limbo as a moat
    EU GMP advantage
    Regulation's hidden winners
    Chapters
    00:00 Federal limbo becomes the business model
    02:17 The reform everyone agrees on
    03:28 Capital markets and the bigger pond
    05:35 Six hundred brands and no patience
    06:55 Why Rochester can move New York
    09:48 Strong operators become obvious
    13:40 The cost of crossing state lines
    16:28 Aurora Curaleaf and scarce EU GMP assets
    20:26 The Canadian future that did not arrive
    22:00 What mature industry compliance could bring
    24:35 Cultivated's nonsecret sauce
    31:41 Cannabis stigma still follows the operator
    32:28 Why Cultivated launched membership
    40:23 Quality media has a real cost
    41:18 California and New York regulators share a market
    44:02 Policy goals that fight each other
    49:06 Competition cooperation and price compression
    52:25 Where to find Jay and Cultivated
    Guest Links
    Jay Rosenthal - Co-Founder and Managing Director of Cultivated Media
    Cultivated Media
    Cultivated events
    Sign up for the Cultivated Daily newsletter
    Our Links
    The Dime Podcast — website
    Bryan Fields on X
    The Dime on X
    The Dime on YouTube
    The Dime on Instagram
    Newton Insights — insights for extraction teams
    Follow The Dime for more conversations on cannabis business, operations, and international markets.
    Share this episode with an operator rethinking their edibles.

    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
  • The Dime

    What Makes Consumers Buy the Same Edible Again? ft. Kim Sanchez Rael

    09/30/2026 | 42 mins.
    Fast-acting edibles can command a premium, but labels such as "nano" do not prove the final product works. The larger operating question is whether the formulation improves taste, shelf stability, manufacturing efficiency, and trust at the same time.
    This week we sit down with Kim Sanchez Rael
    Fast onset economics
    The nano problem
    Science/ AI and so much more
    Fast-acting cannabis edibles promise a more predictable experience, but the language on the package does not always tell operators what happens in the final product.
    Kim Sanchez Rael, President and CEO of Azuca, breaks down what "fast" should mean, why slow-onset edibles still dominate, and how formulation choices affect taste, stability, curing time, shelf life, and production efficiency. She explains why "nano" is often a measurement or marketing label rather than proof of a better consumer outcome, then offers four questions brands should ask any infusion supplier.
    The conversation also moves beyond formulation. Kim describes the economics behind fast-acting products, the role of supplier behavior when production is at risk, the case for a single regulatory framework for the cannabis plant, and why operators cannot build a business that depends on an unpredictable regulatory change.
    Topics include:
    The consumer value of predictable onset
    Manufacturing tradeoffs in gummy formulation
    What brands should demand from infusion partners
    Why structured quality systems matter
    How Azuca uses AI inside its team and customer experience
    Learn more about Azuca and TiME INFUSION® at https://azuca.co/.
    Guest: Kim Sanchez Rael, President and CEO, Azuca
    Host: Bryan Fields, The Dime
    Chapters
    00:01 Why slow-onset edibles still dominate
    01:47 The economics of fast acting
    03:56 Can brands claim "fast"?
    05:56 Predictability and consumer trust
    08:06 The retail education gap
    10:24 How Azuca licensing works
    14:44 Formulation, cannabinoids, and flavor
    15:30 When "fast" does not feel fast
    18:18 Onset, peak, and duration
    20:01 Manufacturing efficiency R&D
    23:14 Validating infusion science
    24:43 Why "nano" is a buzzword
    27:38 The operational cost of change
    28:24 Four questions for infusion suppliers
    30:00 Supplier behavior as brand experience
    32:31 The Fourth of July production rescue
    33:48 What cannabis still gets wrong
    34:15 The One Plant Solution
    37:04 Policy resistance and incrementalism
    38:41 AI and "Kimothy"
    41:21 Quality systems and sustainable math
    44:58 The question Kim wishes people asked
    45:45 Where to find Azuca
    Our Links
    The Dime Podcast — website
    Bryan Fields on X
    The Dime on X
    The Dime on YouTube
    The Dime on Instagram
    Eighth Revolution
    Newton Insights — insights for extraction teams
    Follow The Dime for more conversations on cannabis business, operations, and international markets.
    Share this episode with an operator rethinking their edibles.
    Guest Links
    Kim Sanchez Rael — Azuca

    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
More Business podcasts
About The Dime
Most cannabis companies won't survive the next three years. The ones that do will have better capital discipline, sharper regulatory reads, and operational frameworks built for compression, not growth. The Dime is where cannabis operators, executives, and investors hear directly from the CEOs and founders making those decisions right now: MSO strategy, state-by-state market dynamics, cultivation and extraction economics, brand positioning, and the financing structures keeping companies alive. Bryan Fields hosts weekly conversations built for operators, not observers.
Podcast website

Listen to The Dime, The Ramsey Show and many other podcasts from around the world with the radio.net app

Get the free radio.net app

  • Stations and podcasts to bookmark
  • Stream via Wi-Fi or Bluetooth
  • Supports Carplay & Android Auto
  • Many other app features
The Dime: Podcasts in Family